Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miki Ando

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Stem Cell Reports|March 7, 2017
Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC DerivativesGo Itakura, Soya Kawabata, Miki Ando, et al.
Stem Cell Reports|September 1, 2015
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell TherapyMiki Ando, Toshinobu Nishimura, Satoshi Yamazaki, et al.
Cytotherapy|January 16, 2026
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registryMasatoshi Sakurai, Yasuyuki Arai, Hideki Goto, et al.
Annals of Hematology|November 9, 2023
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosisKotaro Shide, Katsuto Takenaka, Akira Kitanaka, et al.
Hematology (Amsterdam, Netherlands)|April 16, 2024
Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in JapanYoko Edahiro, Tomonori Ochiai, Yoshinori Hashimoto, et al.
International Journal of Hematology|April 14, 2023
Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosisYoko Edahiro, Tomonori Ochiai, Yoshinori Hashimoto, et al.
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Stem Cell Reports|March 7, 2017
Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC DerivativesGo Itakura, Soya Kawabata, Miki Ando, et al.
Stem Cell Reports|September 1, 2015
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell TherapyMiki Ando, Toshinobu Nishimura, Satoshi Yamazaki, et al.
Cytotherapy|January 16, 2026
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registryMasatoshi Sakurai, Yasuyuki Arai, Hideki Goto, et al.
Annals of Hematology|November 9, 2023
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosisKotaro Shide, Katsuto Takenaka, Akira Kitanaka, et al.
Hematology (Amsterdam, Netherlands)|April 16, 2024
Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in JapanYoko Edahiro, Tomonori Ochiai, Yoshinori Hashimoto, et al.
International Journal of Hematology|April 14, 2023
Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosisYoko Edahiro, Tomonori Ochiai, Yoshinori Hashimoto, et al.
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
Pageof 9